These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 24604058)

  • 41. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 42. A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.
    Chung DS; Shin HJ; Hong YK
    J Immunol Res; 2014; 2014():326545. PubMed ID: 25009822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M; Han S; Shi X
    Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cell immunotherapy for malignant gliomas.
    Luptrawan A; Liu G; Yu JS
    Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunobiology of brain tumors.
    Sawamura Y; de Tribolet N
    Adv Tech Stand Neurosurg; 1990; 17():3-64. PubMed ID: 2180410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
    Scutti JAB
    Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic approaches to therapy for brain tumors.
    Paul DB; Kruse CA
    Curr Neurol Neurosci Rep; 2001 May; 1(3):238-44. PubMed ID: 11898524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of local immunoresistance in glioma.
    Albesiano E; Han JE; Lim M
    Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy of malignant gliomas.
    Maleci A
    J Neurosurg Sci; 1989; 33(1):77-82. PubMed ID: 2674361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunomonitoring in glioma immunotherapy: current status and future perspectives.
    Lamano JB; Ampie L; Choy W; Kesavabhotla K; DiDomenico JD; Oyon DE; Parsa AT; Bloch O
    J Neurooncol; 2016 Mar; 127(1):1-13. PubMed ID: 26638171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Galectin-1 and immunotherapy for brain cancer.
    Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
    Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microglia in the Brain Tumor Microenvironment.
    Cole AP; Hoffmeyer E; Chetty SL; Cruz-Cruz J; Hamrick F; Youssef O; Cheshier S; Mitra SS
    Adv Exp Med Biol; 2020; 1273():197-208. PubMed ID: 33119883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell therapy of high-grade gliomas.
    Van Gool S; Maes W; Ardon H; Verschuere T; Van Cauter S; De Vleeschouwer S
    Brain Pathol; 2009 Oct; 19(4):694-712. PubMed ID: 19744041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study.
    Chen PY; Hsieh HY; Huang CY; Lin CY; Wei KC; Liu HL
    J Transl Med; 2015; 13():93. PubMed ID: 25784614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
    Xun Y; Yang H; Kaminska B; You H
    J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for malignant gliomas.
    Bloch O
    Cancer Treat Res; 2015; 163():143-58. PubMed ID: 25468230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.